SECTM1 and cancer: Moreover, SECTM1 has been identified as a potential predictive biomarker for the response to immunotherapy in various types of cancer, showing upregulation in immune-hot tumors and sensitivity to the IFN-γ/STAT1 signaling pathway (16).